Filter Search for grants
Call Navigation
Call key data
Innovation Uptake Call
Funding Program
European Institute of Innovation and Technology
deadlines
Opening
15.07.2026
Deadline
16.09.2026 16:00
Funding rate
50%
Call budget
€ 5,200,000.00
Estimated EU contribution per project
max. € 650,000.00
Link to the call
Link to the submission
Call content
short description
EIT Health is calling for mature digital, data-driven and AI-powered healthcare solutions ready to scale across European markets. Selected projects will receive funding to accelerate market entry, generate real-world evidence, strengthen market access, and support the adoption of clinically validated innovations across healthcare systems.
Call objectives
EIT Health will co-fund collaborative SME- or industry-led projects that focus on new market entry (either first market deployment, or expansion into a new market) and commercial piloting activities for patient-centered digital medical devices (DMDs) and in-vitro diagnostic devices (IVDDs).
Projects should focus on generating robust data to demonstrate economic and commercial viability, and improve market access conditions, through:
- Commercialisation pilots with prospective partners in the target market(s) to test the solution on a small scale.
- Product usability testing and adaptations for the local target market(s).
- Go-to-market strategy development, business model validation, pricing model, commercial partnerships and distribution set-up, etc.
- Health economics analysis to generate evidence on cost-effectiveness and economic value to support adoption and reimbursement.
- Applying for reimbursement pathways, such as national fast-track programmes selective insurance contracts, or other pathways.
Solution eligibility:
- The solution must be a medical device or application as defined in regulations EU 2017/745 (MDR) or EU 2017/746 (IVDR).2 Products that are currently in transition to MDR or IVDR are also eligible.
- The solution must be at an Innovation Maturity Level (IML) of either IML 7 (Validation of Solution) or IML 8 (Approval & Launch) with an obtained CE mark and be preparing for entry into a new market.
- At least 2 sides of the Knowledge Triangle (business, education and research) must be represented within the consortium.
- The Activity Leader of the consortium must be a Commercialising Entity, responsible for commercialising the solution alone or with a partner.
read more
Expected effects and impacts
Funded projects are expected to achieve:
- Launch of the innovation on the market with at least €10 000 revenue within one year post-project.
- Reach at least 150 000 patients or citizens within three years.
- Generate strong clinical, economic, and commercial evidence to support adoption.
- Demonstrate scalable, sustainable business and deployment models across European markets.
Expected results
The Innovation Uptake Call invites organisations from across the Knowledge Triangle (Industry, Education and Research) to submit applications for funding for collaborative projects focused on patient-centric digital health solutions starting at Innovation Maturity Level (IML) 7 - Validation of Solution.
Proposed solutions must go beyond the state-of-the-art, have a clear medical purpose, and meet the definition of a digital medical device or in-vitro diagnostics device according to European regulations MDR 2017/745 and IVDR 2017/746. Proposals must address a critical, unmet healthcare need and harness digital technologies. They should demonstrate tangible health outcomes to patients across one or more stages of the patient care pathway, whether through screening, diagnosis, treatment and/or monitoring.
These devices could include software intended to be used alone or in combination with hardware (e.g. scanners, sensors, monitors, etc.) and include static and self-learning algorithms (e.g. artificial intelligence, machine learning). They can be used by patients, caregivers, healthcare professionals and health system users in the broadest sense.
The following types of innovations are out of scope:
- A non-medical device or application.
- A product primarily designed for wellness or lifestyle purposes that can be used without medical oversight.
- A solution that does not directly address medical conditions or treatments.
- A healthcare management software that does not directly impact patient diagnosis, treatment, or care.
These innovations should have already obtained formal regulatory approval (e.g. CE mark) and demonstrated some early market traction. They should now be at the stage of running real-world commercial pilots, building partnerships and generating additional robust evidence. This evidence can be used to demonstrate the solution’s relevance in the target market, demonstrate economic and commercial viability, test market access conditions, usage, and adoption by healthcare providers, patients and payors.
As such, project proposals should focus on the following activities:
- Commercialisation pilots with one or several potential partners (e.g. health care providers, medical device and health technology companies, etc.) to test the implementation of the solution on a small scale and generate the necessary evidence to secure commercial commitments and deploy the product into the target market.
- Usability testing and product adaptations for the target market (e.g. language, user interface, systems integrations, etc.) before a larger scale launch.
- Go-to-market and business model validation activities (e.g. market analysis, establishing commercial or distribution networks, pricing model, etc.) to ensure the deployment of a commercially sustainable solution in the new target market(s). The activities are expected to lead to the product’s commercialisation in the new target market(s) within a maximum of one year after the end of the EIT Health funding period.
- Health Economics Studies and preparing evidence prior to or for the purpose of a Health Technology Assessment
- Exploring and setting up reimbursement pathways, for example by applying for national fast-track procedures (DiGA, PE-CAN, etc.) or establishing selective insurance contracts.
The funding of pivotal clinical trials to establish evidence of the solution’s safety and efficacy is not eligible. However, funding clinical studies or leveraging ongoing clinical studies to generate clinical and economic evidence for the purposes listed above (e.g. as part of a small-scale pilot or to fulfil the requirements of the local target market) can be included in the project scope. In this case, obtaining all relevant ethical approvals is required and must be demonstrated as part of the project deliverables.
The funded innovation must be based on a viable existing or future business model, backed by robust Intellectual Property Rights and a legally registered, for-profit entity (e.g. a micro, small, medium or large enterprise) acting as the Activity Leader of the project and with the proper capabilities, governance model, partnership agreements and incentives in place to market and scale the solution.
read more
Eligibility Criteria
Regions / countries for funding
Moldova (Moldova), Albania (Shqipëria), Armenia (Հայաստան), Azerbaijan (Azərbaycan), Bosnia and Herzegovina (Bosna i Hercegovina / Босна и Херцеговина), Canada, Faeroes (Føroyar / Færøerne), Georgia (საქართველო), Iceland (Ísland), Israel (ישראל / إِسْرَائِيل), Kosovo (Kosova/Kosovë / Косово), Montenegro (Црна Гора), Morocco (المغرب), New Zealand (Aotearoa), North Macedonia (Северна Македонија), Norway (Norge), Serbia (Srbija/Сpбија), Tunisia (تونس /Tūnis), Türkiye, Ukraine (Україна), United Kingdom
eligible entities
Small and medium-sized enterprise (SME)
Mandatory partnership
Yes
Project Partnership
Who can apply?
- Consortia of at least two independent legal entities from different countries.
- Must include partners from at least two sides of the Knowledge Triangle (Industry, Research, Education).
- Led by a Commercialising Entity (SME or industry player) responsible for bringing the solution to market.
- Applicants must be legal entities (individuals cannot apply).
- Entities must be established in eligible Horizon Europe countries (EU Member States, associated countries, or eligible third countries).
For this call, a ‘legal entity’ means a legal entity created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality.
other eligibility criteria
- Maximum funding of 650,000 EUR per awarded project.
- Grant will cover up to 50% of the total project costs, up to the maximum funding described above.
- Funding to the Commercialising Entity in the case that it qualifies as a micro or small enterprise must be between 400,000 - 500,000 EUR.
- Mandatory Financial Sustainability Contribution Agreement to be signed between EIT Health and the Commercialising Entity.
- If the Commercialising Entity qualifies as a micro or small enterprise, it must demonstrate a minimum level of financial traction of at least EUR 500,000 in the past 3 years from external funding (revenue, equity, or other dilutive sources). Grants or non-dilutive sources do not count against this threshold.
Additional information
Topics
Relevance for EU Macro-Region
EUSAIR - EU Strategy for the Adriatic and Ionian Region, EUSALP - EU Strategy for the Alpine Space, EUSBSR - EU Strategy for the Baltic Sea Region, EUSDR - EU Strategy for the Danube Region
UN Sustainable Development Goals (UN-SDGs)
project duration
15 months
Additional Information
- Step 1: register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation has a PIC number you can check in the EU Portal - click here
- Step 2: apply to the call via EIT Health’s application platform here.
Call documents
Contact

